INSERM CHAIR Recruitment : Identification of dysregulated embryonal programs in pediatric cancers

28 Feb 2024
Job Information

Organisation/Company

INSERM

Department

Departement des Ressources Humaines

Research Field

Medical sciences » Cancer research

Researcher Profile

Established Researcher (R3)
Leading Researcher (R4)

Country

France

Application Deadline

2 Apr 2024 - 17:00 (Europe/Paris)

Type of Contract

Permanent

Job Status

Full-time

Hours Per Week

35

Offer Starting Date

1 Oct 2024

Is the job funded through the EU Research Framework Programme?

Not funded by an EU programme

Is the Job related to staff position within a Research Infrastructure?

No

Offer Description

The Inserm chair recruitments opened to Inserm are intended for researchers with strong potential to manage and lead research teams and participate in national, European or international projects.

This recruitment, based on research and teaching projects, is aimed at researchers with a doctorate or equivalent and a first post-doctoral experience. The position is offered on a fixed-term contract (CDD) with a view to tenure in the Inserm Research Directors personnel at the end of the contract.

Strategy of the host institution :

The Institut Curie (IC) is a private foundation devoted to the fight against cancer. The hospital complex treats all cancers, including the rarest. It devotes considerable space to innovation and clinical research. The IC research center is made up of 13 joint research units in association with the CNRS, Inserm and several IDF universities, a translational research department, and 19 technological platforms brought together in a single entity called CurieCoreTech. It hosts 87 research teams work on 6 themes encompassing the fields of biology, chemistry, physics, and mathematics from fundamental to the most applied aspects. It hosts a large developmental biology research unit.

Clinical and research activities in the field of pediatric oncology are gathered in the care and research SIREDO center headed by Olivier Delattre. It treats all types of pediatric solid tumors and lymphomas. SIREDO has a renown international expertise in clinical, translational and basic research in the fields of brain tumors, neuroblastoma, sarcomas, retinoblastoma, rare tumors and early drugs development. Pediatric research teams are presently dispersed in three research units, the U830 headed by O Delattre hosts the Delattre, Schleiermacher and Bourdeaut teams, the UMR3348/U1021 headed by Arturo Londono hosts the Ayrault and Pouponnot teams and the UMR144 headed by Franck Perez hosts the Radvanyi team. In the future (2025) most pediatric teams should gather in a new unit termed ”childhood Cancer Research Unit” which will be headed by O Ayrault

Strategy of the host laboratory :

More than 100 different cancer types can affect children. These cancers are suspected to emerge from dysregulation of normal embryonic development. The IC pediatric research teams mostly investigate the mechanisms of development of pediatric embryonal brain tumors (medulloblastoma, rhabdoid tumors, other embryonic entities), sarcomas, neuroblastoma and retinoblastoma. They develop a variety of techniques to investigate these tumors including genomics, epigenetics, proteomics, single cell approaches to characterize the tumor cells and the microenvironment. The teams have identified some key driver genetic alterations and developed a variety of cellular and animal models for these cancers. The understanding of cell transformation in pediatric cancers requires a better knowledge of the cell and tissue context in which these alterations are oncogenic. Recent data strongly suggest that cells-of-origin of pediatric cancers are early embryonic precursor cells.

This chair aims to support and intensify this work on the identification of the pediatric cancer precursor cells, on the modeling of their development as well as in consolidating the existing dynamic in pediatric oncology at institute Curie.

Summary of the scientific project :

The scientific project will aim at modeling the early step of the development of pediatric cancers. It will address the spatial and temporal organization of the tissue of origin, the signaling pathway that are at stake to determine the trajectories and differentiation pathways of the cells. It will investigate how the genetic events reprogram the fate of the cells-of-origin. The project will require an excellent training in computational biology to compare at different levels (expression, epigenetic architecture, splicing…) the tumor cells with atlas of normal single cells during embryonic development. It will also require skills to develop spatial proteomics and transcriptomics to precisely investigate the interactions of the cells with their microenvironment both in a tumor and in a normal developmental context. Ability to interact with foetopathologists as well as with developmental biologists will be essential.

The recruited researcher will work within the mentioned framework and is also expected to develop his/her own research on NDDs.

Summary of the teaching project:

The recruited researcher will participate in the teaching bioinformatics at the M2 level in Cancerologie, Paris Saclay as well as in Systems biology, genomics and bioinformatics at université PSL. He/She may also participate at the teaching at Ecole doctorale PSL. He/She will also contribute to post university training of oncopediatricians.

National Research Agency package : 200K€

Other package :

Co-funding (Institut Curie junior PI package)*

Staff support:  300 k€

a start-up funding (consumables, platforms): 120k€

Privileged access to postdoc and PhD programs : 280k€

Remuneration : 3500-5000€ according to research experience

 

 

 

Requirements

Research Field

Medical sciences » Cancer research

Education Level

PhD or equivalent

Additional Information
Selection process

It is expected the recruited researcher to become rapidly a group leader in the GAD team. So the candidate should demonstrate ability to supervise Ph.D students, post-doctoral fellow and technical support staff. She/he should have the capacity to obtain competitive funding to manage her/his group.

Successful candidates are chosen by a selection commission composed of six to ten members, the majority of whom are specialists in the fields of research concerned.

The commission carries out an initial examination of the applications, focused in particular on candidate experience and skills relative to the research and teaching project presented above. A shortlist of candidates is then selected for interview.
Only candidates selected by the selection committee on the basis of their applications will be invited to interview.

The interviews are followed by a deliberation during which selection commission  will discuss the quality, originality and, where appropriate, the interdisciplinarity of the research and teaching projects presented by the candidates, their motivation and their scientific and teaching supervision capacity.

The candidates selected at the end of the selection process will be offered a researcher contract, following approval from the President and CEO of Inserm.

Additional comments

Applications can be submitted online at EVA .

Deadline application: April 2, 2024

It is imperative to contact the laboratory corresponding to the Chair you have applied for in order to build the project with them.

 

Position also open to 'Bénéficiaires de l'Obligation d'Emploi' (disabled persons), as defined in article 27 of law no. 84-16 of January 11, 1984 on statutory provisions for the civil service.

Website for additional job details

https://eva3-accueil.inserm.fr/sites/eva/chaires/2024/Pages/default.aspx

Work Location(s)

Number of offers available

1

Company/Institute

Inserm U830 - Institut Curie

Country

France

City

Paris

Geofield

Where to apply

Website

https://eva3-accueil.inserm.fr/sites/eva/chaires/2024/Pages/default.aspx

Contact

City

Paris

Website

http://www.inserm.fr
https://curie.fr/unite/u830

Street

101 rue de Tolbiac - 75654 Paris Cedex 13

E-Mail

[email protected]
[email protected]

STATUS: EXPIRED